1. Extrapyramidal symptoms and medication use in Mucopolysaccharidosis type III.
- Author
-
Tchan MC and Sillence D
- Subjects
- Adolescent, Adult, Anticonvulsants therapeutic use, Antipsychotic Agents therapeutic use, Basal Ganglia Diseases epidemiology, Benzodiazepines adverse effects, Benzodiazepines therapeutic use, Child, Child, Preschool, Cohort Studies, Female, Humans, Incidence, Lamotrigine, Male, Olanzapine, Risperidone adverse effects, Risperidone therapeutic use, Triazines adverse effects, Triazines therapeutic use, Young Adult, Anticonvulsants adverse effects, Antipsychotic Agents adverse effects, Basal Ganglia Diseases chemically induced, Mental Disorders drug therapy, Mental Disorders etiology, Mucopolysaccharidosis III psychology
- Abstract
Background: We report the case of a 16-year-old male with Mucopolysaccharidosis III type A (Sanfilippo syndrome) who was commenced on risperidone for behaviour management. He rapidly developed extrapyramidal symptoms that have not resolved., Method: The medication histories of 20 patients with Mucopolysaccharidosis III seen at a Lysosomal Storage Diseases Clinic were reviewed to determine the incidence of extrapyramidal side effects., Results: Six patients had been treated with risperidone, olanzapine, or lamotrigine. Five of these patients developed extrapyramidal side effects., Conclusions: The incidence of extrapyramidal side effects was considerably higher than expected. We suggest that these medications be used with considerable caution in these patients.
- Published
- 2009
- Full Text
- View/download PDF